Belite Bio (BLTE) to Release Earnings on Monday

Belite Bio (NASDAQ:BLTE) will likely be posting its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, March 2, 2026 at 4:30 PM ET.

Belite Bio (NASDAQ:BLTE) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.18. On average, analysts expect Belite Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Belite Bio Trading Up 0.4%

BLTE opened at $173.30 on Monday. The stock’s 50 day simple moving average is $170.11 and its 200-day simple moving average is $125.65. The stock has a market cap of $6.82 billion, a PE ratio of -75.35 and a beta of -1.46. Belite Bio has a 1 year low of $49.00 and a 1 year high of $200.00.

Key Headlines Impacting Belite Bio

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: Cantor Fitzgerald published a bullish outlook that analysts say supports upside potential for BLTE shares; this contributed to positive investor sentiment today. Belite Bio (NASDAQ:BLTE) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says
• Positive Sentiment: Morgan Stanley is also cited as forecasting strong price appreciation for Belite Bio, helping lift the stock as momentum and analyst optimism draw buyer interest. Morgan Stanley Forecasts Strong Price Appreciation for Belite Bio (NASDAQ:BLTE) Stock
• Positive Sentiment: An American Banking News item highlights HC Wainwright’s continued bullish stance (Buy, $200 target), which can limit downside even as estimates shift. HC Wainwright Forecasts Strong Price Appreciation for Belite Bio (NASDAQ:BLTE) Stock
• Neutral Sentiment: Reported short‑interest figures appear to show zero shares and a 0.0 days‑to‑cover ratio — likely a data anomaly or reporting issue rather than meaningful new short activity. That makes the short‑interest data neutral for near‑term price direction.
• Negative Sentiment: HC Wainwright reduced its near‑term EPS forecasts in a March 3 research note: Q1 2026 EPS cut from ($0.56) to ($0.71), Q2 from ($0.56) to ($0.72), Q3 from ($0.57) to ($0.73), Q4 2026 from $5.80 to $4.05, and FY2026 from $4.12 to $1.89. Although the firm kept a Buy rating and $200 target, the sizable downward revisions to quarterly and full‑year earnings increase uncertainty around near‑term results and could pressure the stock if upcoming operational or clinical updates fall short. Belite Bio (BLTE) MarketBeat company page

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. BTIG Research set a $187.00 price target on shares of Belite Bio in a research note on Wednesday, December 3rd. Wall Street Zen upgraded shares of Belite Bio from a “sell” rating to a “hold” rating in a research note on Saturday. Mizuho set a $223.00 price objective on shares of Belite Bio in a report on Thursday, February 19th. Bank of America began coverage on shares of Belite Bio in a research report on Monday, January 26th. They set a “buy” rating and a $195.00 target price on the stock. Finally, Maxim Group set a $200.00 target price on shares of Belite Bio in a research note on Tuesday, December 2nd. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $202.33.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC boosted its stake in shares of Belite Bio by 45.2% in the 3rd quarter. Citadel Advisors LLC now owns 10,827 shares of the company’s stock valued at $801,000 after purchasing an additional 3,371 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Belite Bio by 45.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 9,809 shares of the company’s stock worth $726,000 after purchasing an additional 3,052 shares in the last quarter. Barclays PLC acquired a new stake in shares of Belite Bio during the 4th quarter worth about $668,000. Marshall Wace LLP bought a new position in Belite Bio during the 2nd quarter valued at about $547,000. Finally, Polymer Capital Management HK LTD acquired a new position in Belite Bio in the third quarter valued at about $538,000. 0.53% of the stock is currently owned by institutional investors and hedge funds.

Belite Bio Company Profile

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.